Loading...

LVTC

LV

ALVOTECH

(ALVO)

2024 6-K

Financial Update

19 Mar '26

Share Transaction Report

27 Feb '26

Positive Study Results

5 Feb '26

New Agreements

2 Feb '26

Patent Settlement

29 Jan '26

Share Transactions

7 Jan '26

Share Acquisitions

7 Jan '26

Management Change

6 Jan '26

Loan Facility Secured

2 Jan '26

Product Launch Announcement

23 Dec '25

Settlement Agreement

19 Dec '25

Business Update

17 Dec '25

Biosimilar Approval

24 Nov '25

Product Approval

20 Nov '25

Earnings Announcement

17 Nov '25

Court Ruling Favorable

12 Nov '25

Regulatory Approval

6 Nov '25

FDA Response Letter

3 Nov '25

Management Change

22 Oct '25

Marketing Authorization Gra...

6 Oct '25

Biosimilar Approvals

22 Sep '25

Business Update

13 Aug '25

Business Update

28 Jul '25

Management Change

10 Jul '25

Ivers-Lee Acquisition

9 Jul '25

Commercialization Agreement

1 Jul '25

Positive Study Results

25 Jun '25

EMA Approval News

23 Jun '25

Share Transfer Update

12 Jun '25

Partnership Announcement

11 Jun '25

Private Placement

5 Jun '25

Partnership Extension

28 May '25

Alvotech Updates

27 May '25

Management Transaction

9 May '25

Earnings Update

8 May '25

Pharmaceutical Tariffs

7 May '25

FDA Approval Received

5 May '25

Management Change

27 Mar '25

Earnings Announcement

26 Mar '25

UK Approval Announcement

26 Mar '25

Acquisition Announcement

20 Mar '25

FDA Review News

18 Mar '25

FDA Approval Notification

24 Feb '25

FDA Application Accepted

18 Feb '25

FDA Review Acceptance

27 Jan '25

Index Inclusion

23 Dec '24

Financial Results Update

13 Nov '24

Marketing Approval Update

4 Nov '24

FDA Approval Announcement

22 Oct '24

Marketing Application Accepted

10 Oct '24

Business Update

15 Aug '24

Marketing Application Accepted

15 Aug '24

Biosimilar Launch

22 Jul '24

Loan Facility Secured

11 Jul '24

Positive Study Results

2 Jul '24

Share Issuance

2 Jul '24

Financial Results Update

1 Jul '24

Company Update

1 Jul '24

Bond Conversion Update

26 Jun '24

Commercialization Agreement

18 Jun '24

Sales Agreement Secured

14 Jun '24

Annual Meeting Update

11 Jun '24

Marketing License Agreement

11 Jun '24

Loan Agreement Details

7 Jun '24

Financial Results Q1

22 May '24

Product Launch Announcement

21 May '24

Partnership Announcement

21 May '24

Partnership Announcement

30 Apr '24

Positive Clinical Results

25 Apr '24

Strategic Partnership

19 Apr '24

FDA Approval Announcement

16 Apr '24

Regulatory Announcement

22 Mar '24

Earnings Announcement

20 Mar '24

Management Change

1 Mar '24

Share Sale Announcement

26 Feb '24

Market Approval Granted

23 Feb '24

Settlement Announced

15 Feb '24

Positive Clinical Results

29 Jan '24

FDA Reinspection Complete

19 Jan '24

Approval Announced

10 Jan '24

Positive Study Results

3 Jan '24

External Links:

SEC

On October 10, 2024, Alvotech announced that the European Medicines Agency accepted a marketing application for AVT03, a proposed biosimilar for Prolia and Xgeva.

AI Assistant

ALVOTECH

2024

6 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.